The startup is developing a patent-pending drug that targets the biofilm life cycle of Pseudomonas aeruginosa, a key contributor to antimicrobial resistance. This treatment enables effective management of respiratory infections, urinary tract infections, wound infections, and catheter-associated hospital-acquired infections.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
*Pseudomonas aeruginosa* biofilms contribute significantly to antimicrobial resistance, complicating the treatment of various infections. Current methods for managing these infections often prove ineffective due to the bacteria's ability to form resilient biofilms. This resistance leads to persistent respiratory infections, urinary tract infections, wound infections, and catheter-associated hospital-acquired infections.
Solution
Biophys is developing a drug targeting the biofilm lifecycle of *Pseudomonas aeruginosa* to improve the management of antimicrobial-resistant infections. Their approach focuses on disrupting the biofilm formation, making the bacteria more susceptible to traditional antibiotics. This targeted intervention aims to enhance the efficacy of treatments for respiratory infections, urinary tract infections, wound infections, and catheter-associated hospital-acquired infections. By addressing the root cause of resistance, Biophys seeks to provide more effective solutions for patients and healthcare providers. The company also offers R&D consultancy services to medical device and life science companies.
Target Audience
The primary target audience includes patients suffering from *Pseudomonas aeruginosa* infections, healthcare providers seeking effective treatment options, and medical device and life science companies requiring R&D consultancy.
Features
- Patent-pending drug targeting *Pseudomonas aeruginosa* biofilms
- Focus on disrupting biofilm formation to enhance antibiotic susceptibility
- Applicability to respiratory infections, urinary tract infections, and wound infections
- Potential to reduce the incidence of catheter-associated hospital-acquired infections
- R&D consultancy services for medical device and life science companies
- Development of Dose Dr, a smart cartridge and applicator system for safer liquid medication delivery
- Services include microbiology, quality management, product development, and business management